These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22419441)

  • 1. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.
    Manzoni M; Mariucci S; Delfanti S; Rovati B; Ronzoni M; Loupakis F; Brugnatelli S; Tinelli C; Villa E; Falcone A; Danova M
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1187-96. PubMed ID: 22419441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.
    Ronzoni M; Manzoni M; Mariucci S; Loupakis F; Brugnatelli S; Bencardino K; Rovati B; Tinelli C; Falcone A; Villa E; Danova M
    Ann Oncol; 2010 Dec; 21(12):2382-2389. PubMed ID: 20497963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
    Malka D; Boige V; Jacques N; Vimond N; Adenis A; Boucher E; Pierga JY; Conroy T; Chauffert B; François E; Guichard P; Galais MP; Cvitkovic F; Ducreux M; Farace F
    Ann Oncol; 2012 Apr; 23(4):919-27. PubMed ID: 21825101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
    Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.
    Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M
    Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating endothelial cells as a novel marker of angiogenesis.
    Mancuso P; Calleri A; Cassi C; Gobbi A; Capillo M; Pruneri G; Martinelli G; Bertolini F
    Adv Exp Med Biol; 2003; 522():83-97. PubMed ID: 12674213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit.
    Samelis GF; Ekmektzoglou KA; Tsiakou A; Konstadoulakis M
    Hepatogastroenterology; 2011; 58(112):1968-71. PubMed ID: 22024069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
    Hradecká I; Ríhová B; Horová R; Demlová R
    Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer.
    Manzoni M; Rovati B; Ronzoni M; Loupakis F; Mariucci S; Ricci V; Gattoni E; Salvatore L; Tinelli C; Villa E; Danova M
    Oncology; 2010; 79(3-4):187-96. PubMed ID: 21358206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer.
    Gootjes EC; Kraan J; Buffart TE; Bakkerus L; Zonderhuis BM; Verhoef C; Verheul HMW; Sleijfer AS
    Cells; 2020 Jan; 9(1):. PubMed ID: 31948091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
    Kluz J; Kopeć W; Jakobsche-Policht U; Adamiec R
    Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.